-
公开(公告)号：US11447557B2
公开(公告)日：2022-09-20
申请号：US15781043
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. Wilson , Jeremy D. Waight , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Ekaterina V. Breous-Nystrom , Volker Seibert , Takemasa Tsuji , Olivier Léger , Dennis J. Underwood , Marc Van Dijk
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US11414458B2
公开(公告)日：2022-08-16
申请号：US16806374
申请日：2020-03-02
发明人： Donald F. Hunt , Andrew Norris , Ann Michelle English , Jeffrey Shabanowitz , William H. Hilderbrand , Oriana E. Hawkins
摘要： The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.
-
公开(公告)号：US11332536B2
公开(公告)日：2022-05-17
申请号：US16784469
申请日：2020-02-07
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Marc Van Dijk , Ekaterina V. Breous-Nystrom , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Nicholas S. Wilson
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US11053315B2
公开(公告)日：2021-07-06
申请号：US15945779
申请日：2018-04-05
发明人： Barbara Joyce-Shaikh , Luis A. Zuniga , Milan Blanusa , Andrea Claudia Schuster , Kornelia Schultze
摘要： The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
-
公开(公告)号：US11013802B2
公开(公告)日：2021-05-25
申请号：US15834290
申请日：2017-12-07
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： Marc van Dijk , Cornelia Anne Mundt , Gerd Ritter , David Schaer , Jedd David Wolchok , Taha Merghoub , Nicholas Stuart Wilson , David Adam Savitsky , Mark Arthur Findeis , Dennis John Underwood , Jean-Marie Cuillerot , Igor Proscurshim , Olga Shebanova
IPC分类号： C07K16/28 , A61K39/395 , A61P11/00 , A61P35/04 , A61K39/00
摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：US20210130495A1
公开(公告)日：2021-05-06
申请号：US17035015
申请日：2020-09-28
申请人： Agenus Inc.
IPC分类号： C07K16/42
摘要： Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to human Fc gamma receptor IIIA (FcγRIIIA) relative to naturally occurring antibodies and retain good manufacturability. Such heterodimeric proteins are particular useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for making these heterodimeric proteins.
-
公开(公告)号：US20200237885A1
公开(公告)日：2020-07-30
申请号：US16738637
申请日：2020-01-09
申请人： Agenus Inc.
IPC分类号： A61K39/00 , A61K39/39 , C07K14/47 , C07K14/74 , C12Q1/6886
摘要： Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patient's cancer.
-
公开(公告)号：US20200079861A1
公开(公告)日：2020-03-12
申请号：US15781043
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. Underwood , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US10479833B2
公开(公告)日：2019-11-19
申请号：US16165833
申请日：2018-10-19
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： Marc van Dijk , Cornelia Anne Mundt , Gerd Ritter , David Schaer , Jedd David Wolchok , Taha Merghoub , David Adam Savitsky , Nicholas Stuart Wilson
IPC分类号： C07K16/28 , A61K39/395 , A61K47/68 , A61K51/10 , A61K39/00
摘要： The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：US20190010239A1
公开(公告)日：2019-01-10
申请号：US15962673
申请日：2018-04-25
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Ana M. GONZALEZ , Nicholas S. WILSON , Dennis J. UNDERWOOD , Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Roberta ZAPPASODI , Taha MERGHOUB , Jedd David WOLCHOK , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.047 秒)
